Bioavailability Study of Tranylcypromine 10mg Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- To Determine the Bioavailability of Tranylcypromine
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00653393
- Locations
- ๐บ๐ธ
SFBC Ft. Myers, Inc, Ft. Myers, Florida, United States
Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fasting Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00653055
- Locations
- ๐จ๐ฆ
Anapharm, Inc., Sainte-Foy, Quebec, Canada
Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions
Phase 1
Completed
- Conditions
- To Determine Bioequivalence Under Fasting Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2008-04-04
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00653419
- Locations
- ๐จ๐ฆ
Phoenix International Life Sciences, Inc., St-Laurent, Quebec, Canada
Effect of Renal Impairment on the Pharmacokinetics, and Safety of Megestrol Acetate Concentrated Suspension
Phase 1
Terminated
- Conditions
- Healthy
- Interventions
- Drug: Megestrol acetate concentrated suspension 125 mg/mL
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00637403
- Locations
- ๐บ๐ธ
SFBC International, Miami, Florida, United States
Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients
Phase 3
Terminated
- Conditions
- AnorexiaCachexiaWeight Loss
- Interventions
- Drug: Megestrol acetate concentrated suspension 110 mg/mLDrug: Placebo
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2016-06-23
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT00637728
- Locations
- ๐บ๐ธ
Innovative Medical Research of South Florida, Inc, Miami, Florida, United States
๐บ๐ธWestern Maryland Health System, Cumberland, Maryland, United States
๐บ๐ธLowcountry Hematology & Oncology, PA, Mt. Pleasant, South Carolina, United States
Treatment of Cancer-associated Anorexia Using Megestrol Acetate Concentrated Suspension
Phase 3
Terminated
- Conditions
- Weight LossAnorexiaCachexia
- Interventions
- Drug: PlaceboDrug: Megestrol acetate concentrated suspension 110 mg/mLDrug: Megestrol acetate concentrated suspension 60 mg/mL
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Par Pharmaceutical, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT00637806
- Locations
- ๐บ๐ธ
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
๐บ๐ธSummit Oncology Associates, Inc., Akron, Ohio, United States
๐บ๐ธFour Seasons Hospice and Paliative Care, Flat Rock, North Carolina, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath